What to expect from AstraZeneca Q3 earnings
AstraZeneca (NASDAQ:AZN) is scheduled to announce Q3 earnings results on Wednesday, November 9th, before market open.
The consensus EPS Estimate is $0.75 (-30.6% Y/Y) and the consensus Revenue Estimate is $10.86B (+10.1% Y/Y).
Over the last 2 years, AZN has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 5 upward revisions and 3 downward.


Last quarter, AstraZeneca Q2 revenue soared on the back of oncology business and the company raised its FY22 revenue outlook seeing growth in COVID therapy Evusheld.
In Q2, the company said it expects total revenue for 2022 to increase by a low twenties percentage. Meanwhile, Core EPS guidance remains unchanged and is expected to increase by a mid-to-high twenties percentage.
"Given the ongoing performance of our underlying business and the contribution of our COVID-19 medicines, we are updating our revenue guidance for 2022. This has enabled us to increase our R&D investment in the exciting number of pipeline opportunities that can benefit patients and drive long term sustainable growth for our company," said AstraZeneca CEO Pascal Soriot.

In August, Pascal Soriot said that the company is looking to acquire small and mid-sized companies focused on oncology and cardiovascular treatments.
(AZN) has risen ~5% YTD.